# ANNUAL REPORT 2021

Qlife

# INTRO

Healthcare and consumers are ready for simple, convenient, and digital solutions for empowering the individual and the way we access healthcare at home – as a part of the ongoing digital healthcare transformation.

Qlife has developed the highly versatile Egoo.health testing platform, integrating several technologies, which can potentially test for a broad range of biomarkers and viruses – protein based and molecular. The technology is easy to use, holds a low cost, and is suitable for use in people's homes or decentral testing locations.

During 2020 and 2021, Qlife has developed and CE-marked an isothermal PCR- test for the Egoo.health platform, that has proven successful during the Sars-CoV-2 pandemic.

During the peak of the pandemic – from May 2020 to August 2021 – Qlife operated a test centre for Sars-CoV-2 in Copenhagen, servicing a range of private customers fast and reliable test results. Since the summer of 2021, Qlife entered a new phase where turnover is generated from the core products; Egoo devices and capsules.

The speed of recognition from customers has granted Qlife significant sales, valuable customer insights as well as an accelerated experience in all areas of operations.

Late 2021, Qlife signed an agreement with FIND, the global alliance for diagnostics, for funding a 12-month project to develop a novel two-in-one assay for the detection of influenza and Sars-CoV-2 viruses in decentralised healthcare settings primarily for Low- and Middle-income countries.

Qlife is ready to continue the journey of making clinical grade-data easily and quickly accessible, through continued product development and launch of a broad range of tests across conditions and markets in relevant segments. We are paving the way for more biomarkers in preparation for the consumer journey to come.

# CONTENT


SARS-CoV-2

# COMMERCIAL JOURNEY KICK-OFF

Egoo.health gives an answer in

**30** minutes

**98%** sensitivity

**98%** specificity

## SALES

In the first quarter, Qlife delivered its first major order to Denmark's infectious disease agency, Statens Serum Institut, of 50 Egoo.health devices and associated Sars-CoV-2 test capsules.

Shortly after, Qlife signed an exclusive three-year distribution agreement with Aidian OY for the Egoo.health device and Sars-CoV-2 tests for the clinical market in a range of European countries. Qlife's sales to Aidian has gradually increased over 2021 and continues with a strong growth into the first quarter 2022.

Through own sales efforts Qlife sold Egoo devices and Sars-CoV-2 test capsules to other customers in Europe. One of these is the growing Swedish customer Testmottagningen, to whom Qlife has ongoing deliveries of both Egoo devices and capsules.

During the fall, the test centre at Symbion was phased out. Demand decreased significantly and Qlife decided to focus resources on sales and R&D related to core business, and consolidated employees and lab facilities in Ballerup.

## PRODUCTS

### Biomarkers

In January, Qlife CE marked its **Sars-CoV-2** test in the Egoo. health system. The CE mark applies to professional use of the test platform Egoo.health for sale on the European market. The CE mark covers the test platform Egoo.health, i.e., mobile test unit, disposable capsules, and software.

During 2021 the system integration phase of the **PKU biomarker** was completed, and verification and validation initiated. Method comparison studies of the PHE capsule to standard reference tests for PHE has been on-going during the past six months. Clinical data comparisons with samples from the National Center for PKU in the Netherlands, Groningen, and Rigshospitalet, Denmark are ongoing.

The **CRP biomarker** was CE marked for professional use early 2020 according to IVD and the update to IVDR is progressing, as well as protocols and usability studies for home use approval.

With the recent agreement with FIND, the development path within the respiratory area is clear; Qlife will develop a novel two-in-one assay for the detection of **influenza and Sars-CoV-2 viruses** on the Egoo device, financed by FIND. The test is primarily intended for a regulatory approval of WHO and sales to low- and middle-income countries.

The development of an improved blood transfer pipet (PKU and other biomarkers) has been initiated in 2021 and is progressing well. The design is being evaluated.

During 2021, progress was made in the project of freeze drying our reagents to allow capsules to be transported and kept at room temperature. For entry to the home market, freeze drying of all relevant reagents will be essential, and the project is a continued priority.

### Technology and Patent

The biomarker detection unit consists of an integrated optical microelectromechanical system that has a dual optical unit for simultaneously measuring fluorescence and absorbance. The optical unit is integrated on a micro heating and vortex mixing unit for heating and mixing the assay reagents during assay runs. This provides for a small and agile platform that can be operated by laymen people, capable of detection of

60

number of employees in 2021

40 mSEK

sale 2021

121 mSEK

capital raising 2021

## ORGANISATION, MANAGEMENT AND BOARD

During 2021 Qlife's organisation grew to a team of 60 employees. The growth of the organisation along with the phase-out of the testing centre led to an overall organisational change with a consolidated executive management group, and the forming of a separate management group for the R&D and production areas.

Today, the executive management consists of six executives covering Group Management, R&D, Sales, Regulatory, Production and Finance.

At the Annual General Meeting Mette Gross, John Moll, Niklas Marschall and Thomas Warthoe were re-elected as board members, and Mette-Marie Harild, Ulrik Harrysson and Mikael Persson were elected as new board members. Mette Gross was re-elected as chairman of the board of directors. In September Niklas Marschall left the Board of Directors of Qlife.

## FINANCIAL EVENTS

During 2021, Qlife has carried out two financing activities, and thereby secured financing of 121 MSEK.

- In April, a directed share issue of 90 MSEK, mainly to strategic and institutional investors, among others Fjärde AP-fonden, Strand Kapitalförvaltning, Eiffel Investment Group, Nyenburgh Holding and MW Asset Management.
- In May, 4,356,436 warrants of series TO1 were exercised, for subscription of 2,178,218 shares at a subscription price of SEK 17.50 per share. Through the exercise of the warrants, Qlife received 38.1 MSEK before issuing costs.

all kinds of biomarkers (DNA/RNA/Protein).

For Sars-CoV-2 and molecular assays in general, Qlife uses a Polymerase Chain Reaction (PCR) technology called Strand Invasion Based Amplification (SIBA). The tests have a sensitivity of at least 98 percent, and a specificity of 98 percent.

The Danish Patent Office granted Qlife ApS patent for its unique detection method and its biomarker detection unit. The patent is valid until 2039 and gives Qlife a strong intellectual property position. Since then, Qlife has submitted two international patent applications which will provide a similar IP position in relevant jurisdictions abroad.

**Scientific recognition**

A scientific study of the company's Sars-CoV-2 test was published in Natures *Scientific Reports* in November. The study demonstrates the potential of Qlife's mobile test platform Egoo.health and Sars-CoV-2 tests that can deliver almost the same clinical quality as laboratory tests in 30 minutes. The complete study is available in *Scientific Reports* (https://www.nature.com/srep/).

| | Jan-Dec, Q1-Q4 | |
|---|---|---|
| Group - Key figures - kSEK | 2021 | 2020 |
| Revenue | 39,613 | 20,750 |
| Total operating income | 65,194 | 42,636 |
| Total Operating expenses | -100,578 | -62,058 |
| EBITDA | -35,383 | -19,422 |
| Cash flow financing | 105,419 | 58,911 |
| Total cash flow | 52,600 | 15,253 |
| Cash reserve | 73,461 | 20,822 |
| Shareholders´ equity | 163,179 | 89,549 |
| Number of employees | 56 | 34 |

# AN EVENTFUL AND ENCOURAGING YEAR WITH A POSITIVE TRANSFORMATION



Thomas Warthoe - CEO Qlife Holding AB

2021 was a positive year for Qlife with many exciting and encouraging events that will have both short- and long-term effects on the company's development.

On an overall perspective it is interesting to conclude the promising transformation that Qlife has made throughout the year. We started with a slightly different business than we are ending the year with. We entered the year running test centres, now we are selling devices and capsules; our biggest customers were football and other sports clubs at the beginning of the year, now we have customers and partners serving needs in decentralised healthcare settings.

It is essential that we succeeded in making the strategically important transformation from laboratory to platform sales and this has been proved by the numbers during the last quarter of the year. We are now back in line with our core business compared to when we provided laboratory service.

## People have gotten used to decentralised testing

The most important long-term trend change in 2021 for Qlife, is the willingness of people to perform tests at home, which truly supports our long-term business concept and significantly facilitates our ongoing launch work.

During the last two years people all over the world have gotten used to testing, both in test centres and at home. This trend will not just give way, as we will experience virus pandemics continually, which increases the opportunity to test at home. This is a particularly important trend for Qlife, and you can say that the world has changed in this matter. Eventually this trend can ease the launch of a device in the home market, and in the short run, when covid will be endemic instead of pandemic, further increase the need for decentralised testing.

## Sales nearly doubled during the year

Even though we are a company in the development phase, 2021 was promising in terms of sales. The first half of the year developed nicely, but during the third quarter we saw a sales dip. It was important that sales during the fourth quarter bounced back and resulted in Qlife's best quarter so far in terms of sales. For the full year sales nearly doubled to 39.6 MSEK (20.7).

At the end of the year, we had two large and fast-moving customers/distributors; the Swedish company Testmottagningen.se and our Finnish distributor Aidian. Both see a very good demand for our products and are eager to expand their business with us, which means that we see continued good sales opportunities going forward. Testmottagningen.se is also a particularly good example of a health kiosk and therefore fits nicely into our strategy.

For me it was a big relief that we saw a very positive development of the collaboration with our partner Aidian during the end of the year. Initially Aidian started in the clinical sector but shifted focus towards the more decentralised areas, which is working very well, with diverse types of customers in different countries.

Our Sars-CoV-2 product is providing sales and clinical validation in the short-term. The market size is likely to fluctuate across geographic regions as the pandemic effects and testing requirements change.

For the coming year, we will continue our sales efforts of our Sars-CoV-2 product, with the aim of selling everything we can produce, establishing stronger relations with distributors and direct customers, to be able to build upon the established base while bringing new products to the market.

## Reviewed and updated strategy

During the summer and fall 2021, we conducted a review of our strategy, and the process has sharpened our vision, long-term ambitions and goal for market, products, and manufacturing. Qlife's vision is to make clinical-grade biomarker data easily and quickly accessible, and our ambition for the year 2025 is to be a leader when it comes to providing clinical test results outside the lab (for more detailed information on our updated strategy see page 12).

"We are excited to put our specialist knowledge to work in developing a two-in-one respiratory assay based on our device/platform."

Qlife's ambition to establish a market-leading position in consumer health is supported by strategic goals.

- **Strategic market goals**
  Firstly, we shall establish a market-leading position in PKU globally, secondly validate Egoo technology in the clinical retail market and pave the way to consumer health, and thirdly position Qlife as a new player for monitoring services in consumer health.
- **Product development goals**
  Qlife is constantly developing new biomarkers for various indications. Right now, we are focusing on development within three applications: CRP/C-Reactive Protein, PHE/Phenylalanine and Respiratory/Influenza/Sars-CoV-2.
- **Manufacturing goals**
  Capsule production is a core competence and a key factor in our business model. We strive to increase our production capacity and during the fourth quarter we increased it to 20,000 capsules per month. Our target is to double that level during the next two quarters. In parallel, we are investing in automation, and our plan is to build a semi-automated production line with a capacity of 150,000 capsules per month. The plan is to finalise that line during the end of 2022.

  When it comes to device production, we initiated an outsourcing cooperation with a potential manufacturer during the second quarter 2021. The plan is to move over all production of our devices from the middle of 2022. Currently, we have a capacity of 100 devices per month and our immediate goal is to increase it to 1,000 devices per month.

## Important and interesting agreement with FIND

An important and interesting event was the signing of an agreement with FIND, the global alliance for diagnostics (in the context of the Access to Covid-19 Tools (ACT) Accelerator diagnostics pillar), for a funding of 3.45 MUSD for a 12-month project to develop a novel two-in-one assay for the detection of influenza and Sars-CoV-2 viruses in decentralised healthcare settings.


It is a unique opportunity for Qlife to enter a partnership of this scale with FIND. We will now be able to participate in making a difference to people and communities in the targeted countries in the near term. We are excited to put our specialist knowledge to work in developing a two-in-one respiratory assay based on our device/platform, which is always the case, and which constitutes the fundamental for our product strategy.

If we can reach the right pricing, the market is in principle unlimited. At the same time, we get the opportunity to accomplish the development of a multiplex product and are convinced that it will be an excellent product and see possibilities to get it approved for home use. The FDA has stated that they are encouraging multiplex Sars-CoV-2 and influenza products and it is positive that we can follow that trend.

## A competent and experienced organisation

At the end of the year the organisation had sixty employees, which means that we have continued to expand the organisation with competent and experienced employees especially in regulatory affairs, supply chain and software development. We put in a lot of effort to find and keep the right people with the right competence. For many of the assignments within Qlife the employees must have high and specialised education, as well as an experience from the business.

We repeat our assessment that, with this company size, having sixty employees, our company has a good base for further developing the company and rolling out our business plan.

Helsingborg, April 2022

Thomas Warthoe – CEO Qlife Holding AB

# STRATEGY

The characteristics of the Egoo device constitutes a portable size, short time to result and low usage cost opens an array of potential areas of use. We have analysed a series of potential customer groups, segmented by frequency of use, relevant biomarkers, market size and growth, as well as the accessibility to the markets.

The analysis enforced the trends that we see in the healthcare sector as well as amongst societies and consumers:

- Decentralised health and disease monitoring
- Clinical grade data and scientifically validated methods required
- Increasing ageing population – longer lifetime with chronical conditions
- Increased personal interest in monitoring health

During the summer and fall 2021, Qlife conducted a review of its strategy. The strategy process sharpened our vision, long term ambitions and goals for market, products, and manufacturing.

## VISION

Make clinical-grade biomarker data easily and quickly accessible

## OUR AMBITION FOR 2025

By 2025, we will be a leader in providing clinical-grade test results outside the lab.

Qlife's ambition to establish a market-leading position in consumer health is supported by a range of strategic goals until 2025.

# STRATEGIC MARKET GOALS

## 1. Establish a market-leading position in PKU globally

To achieve this strategic goal, we have identified a series of key achievements and milestones that are the foundation for our operational activities.

- Establish presence as preferred PKU monitoring device globally by leveraging key opinion leader networks,
- Become the first-to-market to provide home-testing for PKU patients,
- Achieve data integrations with healthcare systems,
- Secure clinical validation for Egoo.health's use in both clinical and at-home settings.

The PKU market segment suits Qlife's current abilities: regular capsule usage with higher patient loyalty to Egoo.health, in combination with a relatively small user group suitable for Qlife's production capacities. The nature of the PKU patients testing life-long.

**Estimated market**

The total number of PKU patients across selected primary European markets are estimated to approximately 34,000, of which an estimated 30 percent is comfortable with self-administered blood test. The range of testing by patient per year is 12-52, leading to a potential market size of 10.6 million euros.

## 2. Validate Egoo technology in the Clinical Retail market and pave the way to consumer health

During the last two years people all over the world have gotten used to testing outside the healthcare settings, both in test centres and at home. This is a very important trend and an opportunity for Qlife.

The rationale behind addressing the clinical retail market is to further enable consumers testing and monitoring diseases outside the healthcare system, build trust in the test results for consumers and professionals, and validate usability.

Pharmacies (and potentially other retail outlets) purchase Egoo.health to provide 'quick result' testing for customers. Testing may be on a commercial basis or may be funded as part of community-based healthcare arrangements (tapping into trends towards more preventative healthcare approaches).

Egoo.health's strength lies in speed and quality of testing on-site. We define the clinical retail market as pharmacies and health-related clinics (dieticians, physiotherapists, etc). We are evaluating different retail options to find the best fit in different markets.

Retail pharmacies give Egoo.health the opportunity to bridge between the clinical and consumer market.

**Estimated market**

There are an estimated 42,000 pharmacies in the addressable market in Europe, assuming a pharmacy tests 1-6 customers / patients per day, which generates a potential capsule usage of 37 millions annually. However, testing of biomarkers is at large a completely new business area within clinical retail.

The Pharmaceutical Group of the EU (PGEU) estimate that 75 percent of all pharmacies offer glucose monitoring or cholesterol monitoring services. This sub-segment may also be boosted using kiosks in locations such as train stations, airports, and shopping centres.

Community pharmacies and retail clinics have emerged as medical setups where lab tests are performed, but given the direct customer contact, more convenient and quicker time to result would be ideal in these settings.







[1)] *Proxy assumption: The Pharmaceutical Group of the EU (PGEU) estimate that 75% of all pharmacies offer glucose monitoring or cholesterol monitoring services.*

## 3. Position Qlife as a new player for monitoring services in consumer health

Qlife's long-term ambition is to enable everybody to monitor their health using data at their fingertips. Access to the consumer market is essential for Qlife to achieve this ambition. It is intended that this segment will generate the high revenues required to propel Qlife into being the market leader in at-home monitoring.

With 'Consumer Health' as the long-term goal, we foresee PKU and clinical retail providing the preferred pathway to deliver the insights and market validation to reach it.

Lifestyle insights and links to healthcare practitioner advice create a strong 'lifestyle' offer – aligned to wider trends.

The consumer health segment represents a significant market opportunity with an estimated 8.3 million households using technology to monitor their health, chronical diseases, or health & fitness insights, and who are also comfortable with doing a blood-test at home. Usage is estimated to range from four (one person takes a test every quarter) to 16 (two people in a household testing every six weeks).

The market for mobile health-app diagnostics is in its infancy with the landscape currently dominated by activity, exercise instruction and monitoring categories. McKinsey's *Future of Wellness 2021* report identifies health as the biggest category of spend in consumer wellness in Germany and the UK.

There are two prime demographic trends supporting the growth in this segment; the emergent digitally savvy generation and a rising elderly population vulnerable to chronic illnesses who in Europe are moving to self-empowered proactive monitoring within their own home.

## Product portfolio




# PRODUCT DEVELOPMENT GOALS

Qlife is constantly developing new biomarkers for various indications. Development takes place in accordance with the regulatory requirements of the new IVDR and each test is required to be CE-marked before being introduced on the market regardless of professional or at-home use.

### CRP/C-Reactive Protein

During 2022 we expect to finalise CE-mark protocols for CRP and run the necessary usability studies that will allow us to file our CE dossier under the new IVDR to our Notified Body and hence achieve the first clinical-grade CE-mark for a CRP home-testing capsule (CE-marked for professional use since 2020).

### PHE/Phenylalanine (PKU patients)

During 2022 we expect to prepare CE-marking protocols, file the necessary applications for ethical committees and clinical studies with the authorities, and await approval for a clinical trial can start. This is followed by usability studies, which need to be done to confirm that the PKU patients can perform our test by themselves at home. In parallel we are setting up pilot production for the PHE capsule to be able to sustain the volume of capsules necessary for running all the studies.

### Influenza/Sars-CoV-2

Covid-19 represents one of the toughest global health challenges, as does recurrent influenza outbreaks. FIND, in the context of the Access to Covid-19 Tools (ACT) Accelerator diagnostics pillar, aims to accelerate development and delivery of affordable point-of-care, molecular diagnostics in low and middle-income countries.

In December Qlife signed an agreement with FIND, for funding of 3,45 MUSD for a 12-month project to develop a novel two-in-one multiplex assay for the detection of influenza and Sars-CoV-2 viruses in decentralised healthcare settings.

The funding is paid out in three milestone-based payments, with each payment following certain R&D achievements in the development process. Development will ultimately culminate in clinical trials in one or more lower and middle income countries, and a submission of a dossier for regulatory authorisation by the World Health Organization Prequalification Programme.

### Technical development

In addition to the above-mentioned goals for specific biomarkers, the following development projects will be essential to pave the way to enter the intended market segments.

- Finalise pipette design and usability assessment, identify manufacturing options
- Freeze-drying process
- Identify and initiate research on next biomarker (following PKU and CRP)
- Strengthen relationships with KOL and partners in relevant segments
- Data integration doctor-patient in clinical settings (first PKU)

# MANUFACTURING GOALS

In 2021 we reached our goal of capsule production capacity of 20,000 capsules per month. We are planning the move to our new location in April 2022, which will finally allow us to proceed with investments in more efficient semi-automatic production. Our goal is to build a semi-automated production line with a capacity of 150,000 capsules per month. We are aiming at finalising that line during 2022.

Device production and quality control linked to this is made manually and requires significant resources. We initiated a cooperation with a potential manufacturer in 2021 and we are progressing with quality testing their production capabilities for different parts of our device.

So far, we are satisfied with the outcome and are planning to move over all production of our devices from the middle of 2022.

Currently, we have a capacity of 100 devices per month. Our goal is a capacity of 1,000 devices per month, which we expect to reach gradually during 2022 and 2023.

Once we have manufacturing in place in a larger facility, we will be able to begin pilot production for CRP and PKU capsules that will be required for the regulatory process.

# CHAIN OF TEST CLINICS EXPANDS RAPIDLY THANKS TO EGOO.HEALTH

A user-friendly patient journal software and the Egoo.health system form the basis of a new test clinic chain in Sweden.

Alexander Halldin

The first Testmottagningen.se health kiosk opened in May 2021. Nine months later, the company has 12 more clinics in the country's two biggest cities, Stockholm and Gothenburg, and aims to have an additional 12 clinics before summer of 2022. The secret of the company's success has three pillars according to co-founder Alexander Halldin: strategic geographic locations of the clinics in combination with quick test results and high customer satisfaction.

"Our expansion has gone quickly thanks to our platform and our way of doing business," Halldin says. After having hired the first nurses, the four co-founders realised they had to create new software completely adapted to work with digital booking and Egoo.health.

The platform consists of the Egoo.health system and the company's own patient journal software.

"We are very grateful for the Egoo product," Halldin says.

"Without Egoo.health this company wouldn't exist. The fast test results and high reliability are its biggest advantages," he says.

A major part of the 65,000 tests made so far at Testmottagningen.se are PCR tests with Egoo.health. The customers need a negative PCR test result to receive a covid pass before travelling to other countries.

In Sweden the clinics are known as Testmottagningen.se, which literally means the test clinic, but the concept under the brand name Zample has already been exported to the Netherlands, where a franchise partner is starting up test clinics. "We have a long-term strategy with the company, to continue with tests close to patients," explains Halldin. "We all know the pandemic will end sooner or later and now we have proved there is a huge potential for decentralised precise testing. Our idea is to continue to offer testing with different bio markers, such as for PSA [Prostate-specific antigen], chlamydia or measuring the sedimentation rate."

SWEDEN
NORWAY
FINLAND
GERMANY
THE NETHERLANDS
BELGIUM
LUXEMBOURG
AUSTRIA
SWITZERLAND
POLAND
CZECH REPUBLIC
HUNGARY
SLOVAKIA
ROMANIA
SLOVENIA
BALTICS STATES

## WIDESPREAD SALES WITH AIDIAN

Qlife has chosen to partner with Finish distributor Aidian for the sales of the Egoo.health device and the biomarker capsules. Aidian is a market leader in the clinical diagnostics market with an established and widespread salesforce in Europe. "Our relationship with Aidian is crucial to our success," says Rasmus Wagner Møller, Sales & Product Consultant.

The agreement covers a range of European countries, including Sweden, Norway, Finland, Germany, the Netherlands, Belgium, Luxembourg, Austria, Switzerland, Poland, Czech Republic, Hungary, Slovakia, Romania, Slovenia, and the Baltic states.

So far, Sweden and Germany are the largest markets for Qlife followed by Austria, Denmark and Norway. "The biggest segment consists of private test clinics, they like the quick result you get from our platform," Rasmus says. In Germany, Aidian sells to different segments, such as test centres, the offshore industry, pharmacies, retirement homes and schools.

"It makes a lot of sense to use a distributor such as Aidian, as they have great reach and provide solid market insights," says Rasmus.

# “WE CAN REALLY MAKE A DIFFERENCE”

Times are hectic for Qlife’s Director of Research & Development, Maiken Worsøe Rosenstierne. Three projects run in parallel, and the R&D team is growing for every month.

"My job is my passion. I really love the product we have."

Passion. A feeling of intense enthusiasm towards an idea or cause. That kind of eager interest truly defines Maiken Worsøe Rosenstierne's commitment towards her work as R&D Director at Qlife. "My job is my passion. I really love the product we have. I want to make Qlife a success, we can make such a big difference in the world," she says.

She came across the Egoo.health device when working as Senior Scientist at Statens Serum Institut (SSI), which is responsible for the Danish preparedness against infectious diseases. "In the beginning of the pandemic, many people and companies wanted to sell their products to me. We got to test Egoo.health and I had a talk with Peter [Warthoe] and realised the huge potential. This device was what I had been looking for. Earlier, I had worked with the Ebola outbreak in West Africa where there was a need to isolate the infected person and at the same time work close to the patient with diagnostics."

When the corona virus started to spread in 2020, the future of biomarkers completely changed. As a response to the pandemic, Qlife decided to add molecular testing capability to the Egoo system to be able to detect Sars-CoV-2. "This pandemic has helped Qlife. It would have been a difficult task for Qlife to pave the way for home diagnostics, but now it makes sense."

The R&D department follows the design and development plan and Qlife's road map, which includes developing the next

generation of biomarkers. The objectives for 2022 and 2023 are to finish tree big projects. One is to create a new and more sensitive CRP test, which measures the level of c-reactive protein in blood, a clear indicator of inflammation in the patient's body. Another is a biomarker test for PKU (phenylketonuria), a rare but potentially serious inherited disorder. The third one is to build on the existing Sars-CoV-2 biomarker and combine it with an influenza assay. "We're doing well, but since we work with all three projects in parallel, we need to expand our staff."

Finding people with the right competence to the projects is a challenge. Unemployment is very low in Denmark, 2.8 percent in November 2021. Currently, in January 2022 the R&D team consists of 20 employees. "In the next three months, we will be around 30 people in the team. It is crucial to get three new project managers in place, one for each project."

The vibrant company culture is a factor that might attract more talent. "We are all very excited and motivated, our employees can also see the potential. We work hard and want to succeed. When we meet tollgates in our projects, we celebrate our successes."

Timing is a big challenge. "We have to make independent clinical studies, which take a lot of time, especially as the new EU regulative IVDR [In-Vitro Diagnostics Regulative] is not easy on medical devices. But we are here for the long run and will upscale our department regarding technical documentation."

The high-quality standard of the Egoo.health platform works in favour for Qlife in the contacts with healthcare givers. "Hospitals are very positive. The combination of quality, reliability and a competitive price make hospitals interested. Egoo.health is very cheap compared to normal medical equipment."

A recent article published in *Scientific Reports* from Nature's publishing group gives the Egoo.health system another quality stamp, an important step in making an impression on the medical world. "The pandemic has opened the door for us, but it's important that our product is of high quality and clinically approved. We need to publish peer-review studies so that the healthcare sector becomes fully convinced."

**Maiken Worsøe Rosenstierne**

**Title:** Director of R&D

**Education:** Biochemist at University of Copenhagen, MSc and PhD

**Career:** Postdoc at University of Copenhagen and at Roskilde University, Senior Scientist at Statens Serum Institut

**Family:** Husband

**Hobbies:** Gardening, take tours with the camper van to see new places

**An unusual talent:** I have a certificate in repair of boat diesel engines

# HELPING THE WORLD FIGHT PANDEMICS

Qlife aims to accelerate the development and delivery of affordable point-of-care, molecular diagnostics in low and middle-income countries. The project is funded by FIND, the global alliance for diagnostics.

Covid-19 represents one of the toughest global health challenges, as does recurrent influenza outbreaks. To address these challenges, FIND is funding a 12-month project at Qlife with USD3.45 million. The purpose is to develop a new three-in-one assay for the detection of both Sars-CoV-2 and influenza viruses (A and B). Maiken Worsøe Rosenstierne, R&D Director, explains the importance and width of the project.

**Why is the project important for Qlife?**

This project is a huge opportunity for the company. It means an expansion and refinement of our current project for Sars-CoV-2 where we combine it with an influenza test. We will test for three different analytes that give the same symptoms. It can be used in hospitals and in small health care clinics in low and middle-income countries. It will make a big difference for people who don't have access to expensive laboratories – it might prevent new pandemics. American molecular diagnostics company Cepheid started this way and today they sell millions of tests worldwide.

**What exactly is Qlife committed to deliver in 2022? Which are the most important milestones?**

We have 11 different milestones and 41 deliverables to the FIND organisation in the project. We're building the project on the existing Egoo.health system and what we already have developed with the current Sars-CoV-2 capsule. The finished product is a CE-ready assay, supported by documentation and the technical file.

**What resources are needed?**

Apart from our existing R&D team that consists of an assay group, a software group and a hardware group, I have hired a new project manager that runs the project together with me.

**Does Qlife cooperate with other companies to achieve the development milestones?**

We collaborate with Aidian, which developed the reagent for the Sars-CoV-2 capsule. We also collaborate with a company, which

develops a freeze-dried reagent as we can't work with a cold distribution chain for LMIC.

### What development is needed of the Egoo device to succeed with creating a good product?

It needs to be fine-tuned. We look at how we can make it more user friendly, for instance to take the swab directly into the device instead of a pipette. We have to make sure it works in room temperature and in dusty, humid and direct sunlight environments. Also, the reagent needs to be stable in room temperature.

### What are the main challenges?

The limited time frame is a challenge. A possible complication is the current shortage of components due to the corona pandemic.

### How big is the chance to succeed?

Very big, more than 90 percent. We will do whatever it takes to succeed, failure is not an option. I'm very proud to be part of the FIND project and confident we will succeed.

FIND
Diagnosis for all

**About FIND**

FIND, the global alliance for diagnostics, seeks to ensure equitable access to reliable diagnosis around the world. The organisation connects countries and communities, funders, decision makers, healthcare providers and developers to spur diagnostic innovation and make testing an integral part of sustainable, resilient health systems. FIND is working to save one million lives through accessible, quality diagnosis, and save USD1 billion in healthcare costs to patients and health systems. FIND is co-convener of the Access to Covid-19 Tools (ACT) Accelerator diagnostics pillar, and a WHO Collaborating Centre for Laboratory Strengthening and Diagnostic Technology Evaluation.

For more information, please visit **www.finddx.org**

# PROMOTING WELL-BEING FOR ALL

Developing a sustainable company, including a sustainable workplace and consequently sustainable products, is a complex web of culture, innovation, processes, people, and financing.

Qlife is developing innovative monitoring and diagnostic solutions, which can be used in decentralised settings, at affordable prices and with clinical grade quality. The solution can contribute to Global Sustainable Development Goals of UN Agenda 2030 – specifically Goal 3 - Ensure healthy lives and promote well-being for all at all ages – and targets 3.8 and 3.D.

## No 3. Good Health and Well-being.
## Ensure healthy lives and promote well-being for all at all ages.

**Target 3.8**
**Achieve universal health coverage**

Achieve universal health coverage, including financial risk protection, access to quality essential healthcare services and access to safe, effective, quality, and affordable essential medicines and vaccines for all.

**Target 3.D**
**Improve early warning systems for global health risks**

Strengthen the capacity of all countries, in particular developing countries, for early warning, risk reduction and management of national and global health risks.

## Currently, Qlife is pursuing the targets in several ways

1. Giving access to fast, accurate, decentralised and affordable Covid-19 test results through sales in Europe of our Egoo system and Covid-19 test capsules.
2. Preparing for at-home monitoring for Chronic PKU patients globally. We aim for contributing to improved quality of life for PKU patients, by allowing them to individual choices of frequency and location of testing. Potentially we expect better care by additional learning of individuals disease and treatment patterns, allowing adjustments in lifestyle and treatment plans.
3. Preparing for offering decentralised testing of CRP. We aim for contributing to improved quality of life for chronic patients, by allowing them to individual choices of frequency and location of testing. Potentially we expect better care by additional learning of individuals disease and treatment patterns, allowing adjustments in lifestyle and treatment plans.

   Offering decentralised CRP measurements in clinical retailers (for example pharmacies) will allow access to fast and accurate test results, and improved health insights, improved and fast diagnostics, and potentially free resources in the healthcare system.
4. Developing a multiplex assay for Covid-19 and influenza, allowing the same fast and accurate testing with our Egoo system.
5. Preparing a roadmap for large-scale manufacturing of the multiplex assay, to allow a market entry together with partner FIND in low- and middle-income countries (LMIC). It is the specific aim for FIND to accelerate the development, manufacturing, and launch at affordable point-of-care diagnostic platforms in LMIC. It is Qlife's ambition to pursue this acceleration together with FIND.


# GOOD HEALTH AND WELL-BEING

## At Qlife – building a sustainable company

Quality systems and regulatory approvals required to develop and market diagnostic products are extensive, to ensure the products offered are safe and efficient. These requirements go hand in hand with sustainability, as they ensure only high-quality products reach the market.

Qlife is certified according to ISO 13485, which certifies the quality standards we are working in accordance with, covering all development and manufacturing processes in the company. Furthermore, the Egoo system is approved under the European IVD directive 98779/EC. All products must undergo an IVDR approval prior to market launch from 26 May 2022.

Maintaining a healthy, safe, and equal work environment for all employees lays a solid foundation for long-term relations with employees and will help the company safekeep the accumulated knowledge and experience in the long term. This is sound from a financial perspective and sustainable in every perspective.

Keeping high ethical business standards is part of establishing long-term relations with partners and suppliers, which in the business of complex product development is key as development cycles are often long and iterative. Again, this is sound from a financial perspective as well as a sustainable way of doing business in the global context.

# STOCK PRICE UP 28% DURING 2021

Qlife Holding's shares (QLIFE) are listed at Nasdaq First North Growth Market, Stockholm since 2 March, 2020.

## Share and share capital

As per 31 December, 2021, the company's share capital is SEK 1,238,794.16, divided into 15,484,927 shares of the same class, with a par value of SEK 0.08.

In April, Qlife carried out a directed share issue of 2,132,271 new shares raising kSEK 89,555 before issuance costs of kSEK 5,587. The share issue was directed mainly to institutional investors.

## Warrants (TO1)

In May 2021 the TO1 warrants were excercised and 2,178,218 new shares were issued. kSEK 38,119 were received before issuance cost of kSEK 1,144.

The share capital increased by SEK 174,257.

## Ownership and largest shareholders

The table on the next page shows the ten largest share-holders' in the company, as per 31 December, 2021, according to the public nominee register of shareholders' register from Euroclear.

## Incentive programmes

**WARRANTS 2019/2022**

During November 2019, Qlife Holding AB issued 194,444 warrants to the Board of Directors, which entitle the Board of Directors to subscribe for the same number of shares. The warrants can be exercised during the period 1-31 December, 2022 and have a strike price of SEK 24 per share. If all options in this programme are exercised, the Company will issue a total of 194,444 new shares.

## Qlifes stock price




| Shareholder | Shares | Percent |
|---|---|---|
| BNY Mellon SA/NV, Belgium | 3 658 563 | 23,6% |
| JP Morgan Chase Bank NA | 1 220 150 | 7,9% |
| Försäkringsbolaget Avanza Pension | 832 532 | 5,4% |
| Fjärde AP-Fonden | 740 000 | 4,8% |
| Nordnet Pensionsförsäkring | 278 827 | 1,8% |
| Leif Jonsson | 250 000 | 1,6% |
| Société Général Nantes | 238 100 | 1,5% |
| KMD Venture A/S | 163 216 | 1,1% |
| John Andersson Moll | 107 874 | 0,7% |
| Mikael Gunnarsson | 100 000 | 0,6% |
| Total 10 | 7 589 262 | 49,0% |
| Others | 7 895 665 | 51,0% |
| **Sum** | **15 484 927** | **100,0%** |

### WARRANTS 2021/2024

In May 2021, Qlife issued 40,000 warrants to members of the Board, which entitle holders to subscribe for an equal number of shares. The warrants can be exercised during the period of 1–31 May 2024 at an exercise price of SEK 67.08 per share. In the event that all warrants in this programme are exercised, the Company will issue a total of 40,000 new shares.

### STAFF WARRANTS 2019/2022

In November 2019, Qlife Holding AB issued 291,664 employee stock options to employees entitling to subscription of the same number of shares. The stock options can be exercised during the period 1-31 December 2022 and have a strike price of SEK 24 per share. If all options in this programme are exercised, the Company will issue a total of 291,664 new shares.

### STAFF WARRANTS 2020/2023

In November 2020, Qlife Holding AB issued 185,000 employee stock options to employees entitling to subscription of the same number of shares. The stock options can be exercised during the period of 1-31 December, 2023 and have a strike price of SEK 38 per share. If all options in this programme are exercised, the Company will issue a total of 185,000 new shares.

## Nomination Committee

A Nomination Committee to prepare proposals for the Company's Annual General Meeting 2022 has been convened. The Nomination Committee consists of the following persons, who together represent approximately 25 percent of the company's shares and votes:

Sören Skjärbäk, appointed by Thomas Warthoe, Anita Otterheim Hjalmarsson, appointed by Peter Warthoe, Lars Bangsgaard, representing own shares, and Mette Gross, Chairman of the Board.

The Nomination Committee's proposal will be presented in the notice convening the Annual General Meeting 2022 and on the company's website, www.qlifeholding.com.



# Q-LIFE IN FIGURES 2021

# MANAGEMENT REPORT

The Board of Directors and the CEO present the following annual report and consolidated accounts for Qlife Holding AB, Id. no. 559224-8040 for the financial year 2021-01-01 – 2021-12-31.

The annual report has been prepared in thousands of Swedish kronor, TSEK.

## Operations

The company has been listed on Nasdaq, First North Growth Market, Stockholm since March 2, 2020.

Qlife Holding AB is a 100 percent owner of Qlife Aps, a Danish medical technology company that develops an innovative medical technology product with the long-term goal of giving people access to secure and validated biomarker data in the home. Qlife's technical platform, Egoo.health ("Egoo"), consists of a measuring instrument, Egoo, with associated capsules, where each capsule contains a test for a specific biomarker that can be measured with a blood sample.

Egoo acts as a platform as it can potentially perform tests on various types of diseases based on a small amount of blood. To expand the platform to test for more diseases, new capsules only need to be developed.

Egoo has the capacity to perform analyzes that correlate to over 99 percent with high-performance laboratory instruments.

The company's registered office is in Helsingborg.

| Group | 2021 | 2020 | 2019** |
|---|---|---|---|
| Net sales | 39,613 | 20,750 | - |
| Loss after financial items | -54,863 | -31,939 | -5,271 |
| Balance sheet total | 193,435 | 127,189 | 76,596 |
| Equity ratio (%) | 84.4% | 70.4% | 81.6% |

| Parent company | 2021 | 2020 | 2019 |
|---|---|---|---|
| Net sales | 700 | 700 | 175 |
| Loss after financial items | -48,300 | -43,190 | -887 |
| Balance sheet total | 146,690 | 88,898 | 73,154 |
| Equity ratio (%) | 99.6% | 82.2% | 91.9% |

*** Definitions of key ratios, see notes**

**** The Group was founded 31 October, 2019 and the figures show 2 months.**

## Ownership

BNY Mellon SA/NV, Belgien holds 23.6% ie over 10% of the shares in the company as of 31 December, 2021. Founders hold 3,909,953 shares included in the BNY Mellon SA/NV.

## Significant events during the year

During the second quarter Qlife raised 121.2 MSEK (after issuance cost) through a directed share issue and exercise of the warrants of series TO1. Number of shares increased by 4,310,489 to 15,484,927 shares and the share capital with TSEK 345 to TSEK 1,239.

Revenue during 2021 amounted to TSEK 39,613 and includes sales of Covid-19 tests from service centres as well as Egoo.health devices and capsules for decentralised testing.

For further information, see page 8 in other information.

## Significant events after the year end

There are no significant events to report after the end of the financial year.

# CHANGES IN SHAREHOLDERS EQUITY, GROUP

| TSEK | Share capital | Other paid in capital | Retained earnings | Total shareholders equity |
|---|---|---|---|---|
| Balance at the beginning of the year | 894 | 116,164 | -27,509 | 89,549 |
| Share issue | 345 | 127,330 | - | 127,675 |
| Issuance costs | - | -6,731 | - | -6,731 |
| Warrant programmes | - | 244 | 204 | 448 |
| Loss for the year | - | - | -48,838 | -48,838 |
| Foreign exchange rate adjustment | - | - | 1,076 | 1,076 |
| Balance at the end of the year | 1,239 | 237,007 | -75,067 | 163,179 |

# CHANGES IN SHAREHOLDERS' EQUITY, PARENT COMPANY

| TSEK | Share capital | Non-restricted equity | Total shareholders equity |
|---|---|---|---|
| Balance at the beginning of the year | 894 | 72,185 | 73,079 |
| Share issue | 345 | 127,330 | 127,675 |
| Issuance costs | - | -6,731 | -6 731 |
| Warrant programmes | - | 448 | 448 |
| Loss for the year | - | -48,300 | -48,300 |
| Balance at the end of the year | 1,239 | 144,932 | 146,171 |

**Proposed appropriations of profit or loss**

| | |
|---|---|
| The following funds (SEK) are available to the annual general meeting | |
| Retained earnings | 193,232,364 |
| Loss for the year | -48,299,689 |
| | |
| The Board of Directors proposes the following distribution: | |
| To be retained | 144,932,675 |

The financial result and position of the company in general is set out in the income statement, balance sheet, cash flow statement and notes below.

# INCOME STATEMENT, GROUP

| TSEK | Note | 2021-01-01<br>2021-12-31 | 2020-01-01<br>2020-12-31 |
|---|---|---|---|
| **Operating income etc.** | | | |
| Net sales | | 39,613 | 20,750 |
| Capitalised development costs | | 25,581 | 21,886 |
| **Operating expenses** | | | |
| Raw material and consumables | | -20,653 | -6,953 |
| Other external expenses | | -40,056 | -30,826 |
| Personnel costs | 2 | -39,869 | -24,279 |
| Depreciation of tangible assets and amortisation of intangible assets | | -19,479 | -11,902 |
| **Operating loss** | | **-54,863** | **-31,324** |
| Interests expenses and similar items | 4 | -1,478 | -615 |
| **Loss after financial items** | | **-56,341** | **-31,939** |
| Tax | | 7,503 | 11,739 |
| **Net loss for the year** | | **-48,838** | **-20,200** |

# BALANCE SHEET, GROUP

| TSEK | Note | 2021-12-31 | 2020-12-31 |
|---|---|---|---|
| **ASSETS** | | | |
| **Fixed assets** | | | |
| **Intangible assets** | | | |
| Capitalised development costs | 5 | 55,193 | 35,254 |
| Goodwill | 6 | 30,757 | 41,612 |
| **Tangible assets** | | | |
| Plant and machinery | 7 | 2,353 | 2,331 |
| Equipment, tools, fixtures and fittings | 8 | 1,948 | 2,836 |
| **Total fixed assets** | | **90,251** | **82,033** |
| **Current assets** | | | |
| **Inventories etc.** | | | |
| Raw material and consumables | | 8,309 | 5,377 |
| **Short term receivables** | | | |
| Accounts receivables | | 2,755 | 9,329 |
| Other receivables | | 3,885 | 359 |
| Tax receivables | | 7,564 | 7,421 |
| Prepaid expenses and accrued income | 11 | 7,210 | 1,848 |
| **Cash and bank balances** | | | |
| Cash and bank balances | | 73,461 | 20,822 |
| **Total current assets** | | **103,184** | **45,156** |
| **TOTAL ASSETS** | | **193,435** | **127,189** |

| TSEK | Note | 2021-12-31 | 2020-12-31 |
|---|---|---|---|
| **EQUITY AND LIABILITIES** | | | |
| **Equity, Group** | | | |
| Share capital | 12 | 1,239 | 894 |
| Share premium reserve | | 237,007 | 116,164 |
| Retained earnings included the loss for the year | | -75,067 | -27,509 |
| **Total equity, Group** | | **163,179** | **89,549** |
| **Long-term liabilities** | | | |
| Liabilities to credit institutions | 13 | 2,763 | 3,348 |
| **Total long-term liabilities** | | **2,763** | **3,348** |
| **Current liabilities** | | | |
| Advance payment from customers | | - | 600 |
| Liabilities to credit institutions | 13 | 939 | 700 |
| Accounts payable | | 10,027 | 11,607 |
| Other liabilities | | 1,091 | 18,222 |
| Accrued expenses and deferred income | 14 | 15,436 | 3,163 |
| **Total current liabilities** | | **27,493** | **34,292** |
| **TOTAL EQUITY AND LIABILITIES** | | **193,435** | **127,189** |

# CASH FLOW STATEMENT, GROUP

| TSEK | Note | 2021-01-01<br>2021-12-31 | 2020-01-01<br>2020-12-31 |
|---|---|---|---|
| **Operating activities** | | | |
| Loss after financial items | | -56,341 | -31,939 |
| Adjustments for non-cash items, etc. | | 27,613 | 14,188 |
| **Cash flow from operating activities before working capital changes** | | **-28,728** | **-17,751** |
| **Cash flow from working capital changes** | | | |
| Increase in inventories | | -2,805 | -3,314 |
| Increase in receivables | | -2,025 | -10,646 |
| Increase in current liabilities | | 7,507 | 14,882 |
| **Cash flow from operating activities** | | **-26,051** | **-16,829** |
| **Investing activities** | | | |
| Investments in intangible assets | | -25,062 | -21,448 |
| Investments in tangible assets | | -1,706 | -5,381 |
| **Cash flow from investing activities** | | **-26,768** | **-26,829** |
| **Financing activities** | | | |
| New share issue | | 120,600 | 44,450 |
| Warrant program | | 244 | - |
| Changes in loans | | -15,425 | 14,461 |
| **Cash flow from financing activities** | | **105,419** | **58,911** |
| **Cash flow for the year** | | **52,600** | **15,253** |
| Cash and cash equivalents at the beginning of the year | | 20,822 | 4,044 |
| Exchange rate differences in cash and cash equivalents | | 39 | 1,525 |
| **Cash and cash equivalents at the end of the year** | | **73,461** | **20,822** |

# INCOME STATEMENT, PARENT COMPANY

| TSEK | Note | 2021-01-01<br>2021-12-31 | 2020-01-01<br>2020-12-31 |
|---|---|---|---|
| **Operating income etc.** | | | |
| Net sales | | 700 | 700 |
| **Operating expenses** | | | |
| Other external expenses | | -6,179 | -2,894 |
| Personnel costs | 2 | -966 | -702 |
| **Operating loss** | | **-6,445** | **-2,896** |
| **Result from financial items** | | | |
| Depreciation of investment i subsidiary | | -41,259 | -40,476 |
| Interests income from group companies | 3 | 301 | 266 |
| Interests expenses and similar items | 4 | -897 | -84 |
| **Loss after financial items** | | **-48,300** | **-43,190** |
| **Net loss for the year** | | **-48,300** | **-43,190** |

# BALANCE SHEET, PARENT COMPANY

| TSEK | Note | 2021-12-31 | 2020-12-31 |
|---|---|---|---|
| **ASSETS** | | | |
| **Financial assets** | | | |
| Participation in group companies | 9 | 68,024 | 68,024 |
| **Total financial assets** | | **68,024** | **68,024** |
| **Current assets** | | | |
| **Short term receivables** | | | |
| Receivables from group companies | 10 | 21,386 | 5,168 |
| Other receivables | | 108 | 171 |
| Prepaid expenses and accrued income | 11 | 8 | 8 |
| **Cash and bank balances** | | | |
| Cash and bank balances | | 57,164 | 15,527 |
| **Total current assets** | | **78,666** | **20,874** |
| **TOTAL ASSETS** | | **146,690** | **88,898** |
| **TOTAL ASSETS** | | | |
| **Current assets** | | | |
| **Restricted equity** | | | |
| Share capital | 12 | 1,239 | 894 |
| Non-restricted equity | | | |
| Share premium reserve | | 236,923 | 116,080 |
| Retained earnings | | -43,691 | -705 |
| Loss for the year | | -48,300 | -43,190 |
| **Total equity** | | **146,171** | **73,079** |
| **Current liabilities** | | | |
| Accounts payable | | 128 | 198 |
| Other liabilities | | - | 15,004 |
| Accrued expenses and deferred income | | 391 | 617 |
| **Total current liabilities** | | **519** | **15,819** |
| **TOTAL EQUITY AND LIABILITIES** | | **146,690** | **88,898** |

# CASH FLOW STATEMENT, PARENT COMPANY

| TSEK | Note | 2021-01-01<br>2021-12-31 | 2020-01-01<br>2020-12-31 |
|---|---|---|---|
| **Operating activities** | | | |
| Loss after financial items | | -48,300 | -43,190 |
| Adjustments for non-cash items, etc.: | | | |
| Depreciation of investment in subsidiary | | 41,259 | 40,476 |
| Other | | 204 | 86 |
| **Cash flow from operating activities before working capital changes** | | **-6,837** | **-2,628** |
| **Cash flow from working capital changes** | | | |
| Decrease in receivables | | 62 | 909 |
| Decrease in accounts payable | | -71 | 13 |
| Decrease in current liabilities | | -226 | 212 |
| **Cash flow from operating activities** | | **-7,072** | **-1,494** |
| **Investing activities** | | | |
| Loan to subsidiary | | -57,476 | -42,422 |
| **Cash flow from investing activities** | | **-57,476** | **-42,422** |
| **Financing activities** | | | |
| New share issue | | 127,675 | 50,513 |
| Issuance cost | | -6,730 | -6,063 |
| Warrant programme | | 244 | - |
| Changes in loans | | -15,004 | 14,213 |
| **Cash flow from financing activities** | | **106,185** | **58,663** |
| **Cash flow for the year** | | **41,637** | **14,747** |
| Cash and cash equivalents at the beginning of the year | | 15,527 | 780 |
| **Cash and cash equivalents at the end of the year** | | **57,164** | **15,527** |

# NOTES

## Note 1 Accounting principles

The annual report has been prepared in accordance with the Swedish Annual Accounts Act and as well as the Swedish Accounting Standards Board BFNAR 2012: 1 Annual Report and Consolidated Accounts (K3).

### Receivables

Receivables have been raised to the amounts by which they are expected to be received.

### Other assets, provisions and liabilities

Other assets, provisions and liabilities have been valued at acquisition value unless otherwise stated below.

### Revenue recognition

Sales of goods
Income is reported at the fair value of what has been received or will be received. Sales of goods are reported when the company has transferred to the buyer the significant risks and benefits associated with ownership, normally when the customer has the goods in his possession. Deductions are made for discounts.

Services
Revenue from consulting services is recognised as revenue when the services are provided.

### Tangible fixed assets

Tangible fixed assets are reported at acquisition value less accumulated depreciation and any write-downs. The assets are amortised on a straight-line basis over the assets' estimated useful life. The useful life is reconsidered on each balance sheet date. The following periods of use apply:

| | Number of years |
|---|---|
| Machinery and other technical installations | 5 |
| Equipment, tools and machines | 5 |

### Intangible assets

Intangible fixed assets are reported at acquisition value less accumulated depreciation and any write-downs. The assets are amortised on a straight-line basis over the assets' estimated useful life. The useful life is reconsidered on each balance sheet date. Ongoing projects are not depreciated but are tested for impairment annually. The following periods of use apply:

| | Number of years |
|---|---|
| Capitalized expenditure on development and similar works | 5 |
| Goodwill | 5 |

### Capitalisation of internally generated intangible fixed assets

The capitalisation model
All expenses incurred during the research phase are expensed as incurred. All expenses incurred during the development phase are capitalised when the following conditions are met; the company intends to complete the intangible asset and to use or sell it and the company has the ability to use or sell the asset, it is technically possible for the company to complete the intangible asset so that it can be used or sold and there are adequate technical, financial and other resources to complete the development and to use or sell the asset, it is likely that the intangible asset will generate future economic benefits and the company can reliably calculate the expenses attributable to the asset during its development.

The acquisition value includes personnel costs incurred in the work with the development work together with an appropriate proportion of relevant overheads and borrowing costs.

### Financial instruments

Accounts receivables are valued at acquisition value less feared losses. Accounts payable and other non-interestbearing liabilities are valued at nominal amounts.

### Leasing

All leasing agreements are expensed on a straight-line basis over the leasing period.

### Inventory

Inventories are valued at the lower of acquisition value, calculated according to first-in-first-out, and net sales value. The net sales value has been calculated at the sales value after deduction of the estimated sales cost, with which obsolescence has been taken into account.

### Income tax

Current tax is income tax for the current financial year that refers to the taxable profit for the year and the part of the previous financial year's income tax that has not yet been eported. Current tax is valued at the probable amount according to the tax rates and tax rules that apply on the balance sheet date.

The amount that is estimated to be received regarding the tax deficit attributable to research and development expenses during 2021, is reported in the income statement for 2021.

### Share-based payments

On 13 November 2019, it was decided to issue 291,664 warrants, which employees of the subsidiary Qlife ApS were offered to subscribe. The warrants were issued free of charge. Earnings of warrants take place by 1/3 (one third) annually and the cost for the year in the income statement amounts to SEK 40 thousand, which is reported as equity.

Each warrant gives the right to subscribe for a new share in the company against cash payment at a price of SEK 24 / share, between 1 December 2022 and 31 December 2022. The options cannot be transferred.

On 13 November 2019, it was decided to issue 194,444 warrants, which board members in the company was offered to acquire. For all options, an option premium was paid which was reported as equity. The option premium corresponds to the market value of the warrants calculated according to the Black & Scholes option valuation and amounted to SEK 0.43 / option at the time of allotment.

Each warrant gives the right to subscribe for a new share in the company against cash payment at a price of SEK 24 / share, between 1 December 2022 and 31 December 2022.

There are no restrictions regarding the transfer of the options.

On 19 November 2020, it was decided to issue 185,000 warrants, which employees of the subsidiary Qlife ApS was offered to subscribe. The warrants are issued free of charge. Earnings of warrants take place by 1/3 (one third) annually and the cost for the year in the income statement amounts to SEK 164 thousand, which has been reported as equity.

Each warrant gives the right to subscribe for a new share in the company against cash payment at a price of SEK 38 / share, between 1 December 2023 and 31 December 2023.

In May 2021 it was decided to issue 40,000 warrants, which new board members in the company was offered to acquire. For all options, an option premium was paid which was reported as equity. The option premium corresponds to the market value of the warrants calculated according to the Black & Scholes option valuation and amounted to SEK 6.11 / option at the time of allotment.

Each warrant gives the right to subscribe for a new share in the company against cash payment at a price of SEK 67.08/ share, between 1 May 2024 and 31 May 2024.

**Receivables and liabilities in foreign currency**

Monetary receivables and liabilities in foreign currency have been translated at the exchange rate on the balance sheet date.

Exchange rate differences that arise when adjusting or translating monetary items are reported in the income statement in the financial year in which they arise, either as an operating item or as a financial item based on the underlying business event.

**Public grants**

Public contribution is valued at the fair value of the asset that the company has received or will receive.

Public grants that are not associated with requirements for future performance, so-called unconditional grants, are recognised as income when the conditions for receiving the grant are met, ie usually in connection with receiving a grant.

Public grants that are associated with future performance requirements, so-called conditional grants, are recognised as a liability when the grant is received and subsequently recognised as income when the performance is performed.

Government grants relating to the acquisition of a fixed asset reduce the acquisition value of the asset.

**Consolidated financial statements**

Subsidiary

Subsidiaries are companies in which the parent company directly or indirectly holds more than 50% of the voting rights or otherwise has a controlling influence. Controlling influence means a right to formulate a company's financial and operational strategies in order to obtain financial benefits. The reporting of business acquisitions is based on the unit view. This means that the acquisition analysis is prepared as of the time when the acquirer acquires a controlling influence. From this point on, the acquirer and the acquired entity are seen as an accounting entity. The application of the unit view also means that all assets (including goodwill) and liabilities as well as income and expenses are included in their entirety also for partly owned subsidiaries.

The acquisition value for subsidiaries is calculated at the sum of fair value at the time of acquisition for paid assets with the addition of incurred and acquired liabilities as well as issued equity instruments, expenses that are directly attributable to the business combination and any additional purchase consideration. The acquisition analysis determines the fair value, with some exceptions, at the time of acquisition of acquired identifiable assets and assumed liabilities as well as minority interests. Minority interest is valued at fair value at the time of acquisition. From the time of acquisition, the consolidated accounts include the acquired company's revenues and expenses, identifiable assets and liabilities as well as any goodwill or negative goodwill incurred.

The financial statements of foreign subsidiaries have been translated into Swedish kronor according to the current exchange rate method. The current exchange rate method means that all assets, provisions and other liabilities are translated at the exchange rate on the balance sheet date and all items in the income statement are translated at the average exchange rate for the year. Translation differences that arise are recognised directly in the Group's equity.

Goodwill

Group goodwill arises when the acquisition value upon acquisition of shares in subsidiaries exceeds the value of the acquired company's identifiable net assets determined in the acquisition analysis. Goodwill is reported at acquisition value less accumulated depreciation and any write-downs.

**Employees**

Qlife Holding AB has 0 (1) employees, and the Group has 56 (34) employees at the end of 2021.

## Note 2

| Employees and personnel costs | Group | | Parent company | |
|---|---|---|---|---|
| | 2021 | 2020 | 2021 | 2020 |
| **Average number of employees** | | | | |
| The average number of employees is based on what the company paid attendance hours related to normal working hours. | | | | |
| Average number of employees | 39.4 | 20.3 | 0.0 | 0.3 |
| of which women | 20.3 | 9.7 | 0.0 | 0.3 |
| of which men | 19.1 | 10.6 | - | - |
| **Salaries, remunerations tc.** | | | | |
| Salaries, remunerations, social security and pension costs have been paid in following amounts: | | | | |
| Directors and CEO: | | | | |
| Salaries and remunerations | 2,034 | 1,700 | 575 | 420 |
| Social security | 183 | 70 | 181 | 60 |
| Pensions | - | - | - | - |
| Other employees: | | | | |
| Salaries and remunerations | 33,374 | 20,132 | - | - |
| Social security | 403 | 130 | - | - |
| Pensions | 1,433 | 772 | - | - |
| **Total Directors, CEO and other** | **37,427** | **22,804** | **756** | **480** |
| **Gender distribution of the Board and management** | | | | |
| Board of Directors | 6 | 4 | 6 | 4 |
| of which women | 2 | 1 | 2 | 1 |
| of which men | 4 | 3 | 4 | 3 |
| Management incl. CEO | 1 | 1 | 1 | 1 |
| of which women | 0 | 0 | 0 | 0 |
| of which men | 1 | 1 | 1 | 1 |

## Note 2 cont.

| Personnel | Group | | Parent company | |
|---|---|---|---|---|
| | 2021 | 2020 | 2021 | 2020 |
| **Senior management remunerations** | | | | |
| Fees and other remunerations to member of the board are approved by resolution by general meeting of shareholders. | | | | |
| In 2021 paid board fees amounted to: | | | | |
| Mette Gross, Chairman of the board* | 215 | 118 | 215 | 118 |
| John Andersson Moll, Member of the board | 94 | 39 | 94 | 39 |
| Niklas Marschall, Member of the board | 65 | 39 | 65 | 39 |
| Ulrik Harryson, Member of the board | 67 | - | 67 | - |
| Mette-Marit Harild, Member of the board | 67 | - | 67 | - |
| Mikael Persson, Member of the board | 67 | - | 67 | - |

* On 1 November 2019 the chairman of the board Mette Gross entered a 6-month fixed-term employment as a senior adviser in the parent company. In 2020 the total remuneration was 224 TSEK.

| Personnel | Group | | Parent company | |
|---|---|---|---|---|
| | 2021 | 2020 | 2021 | 2020 |
| **Remuneration to the Chief Executive Officer and other senior management in subsidiary company:** | | | | |
| Thomas Warthoe, Chief Executive Officer | 1,555 | 1,280 | - | - |
| Other member of senior management, 6 (3) individuals | 9,005 | 3,786 | - | - |

The company has no provisions, accrued pensions or similar obligations due after resignations from board member or member of senior management. A 6 months' notice period applies if agreement is terminated.

## Note 3

| Other interest income and similar items | Group | | Parent company | |
|---|---|---|---|---|
| | 2021 | 2020 | 2021 | 2020 |
| Interests | - | - | 301 | 266 |

## Note 4

| Other interest costs and similar items | Group | | Parent company | |
|---|---|---|---|---|
| | 2021 | 2020 | 2021 | 2020 |
| Exchange differences | -74 | -64 | - | - |
| Other interest costs | -1,404 | -551 | -897 | -84 |
| | **-1,478** | **-615** | **-897** | **-84** |

## Note 5

| Capitalised development costs and similar work | Group | | Parent company | |
|---|---|---|---|---|
| | 2021-12-31 | 2020-12-31 | 2021-12-31 | 2020-12-31 |
| Cost opening balance | 35,254 | 15,190 | | |
| Translation difference | 837 | -1,384 | | |
| Purchase | 25,062 | 21,448 | - | - |
| Accumulated cost, closing balance | 61,153 | 35,254 | - | - |
| Depreciation opening balance | - | - | - | - |
| Depreciation for the year | -5,960 | - | - | - |
| Accumulated depreciation, closing balance | -5,960 | - | - | - |
| **Carrying amount** | **55,193** | **35,254** | **-** | **-** |
| Of unfinished development work | 17,662 | 35,254 | - | - |
| Asset purchased with public grant is included with reported cost value | 3,333 | 2,548 | - | - |

## Note 6

| Goodwill | Group | | Parent company | |
|---|---|---|---|---|
| | 2021-12-31 | 2020-12-31 | 2021-12-31 | 2020-12-31 |
| Cost opening balance | 54,276 | 54,276 | - | - |
| Accumulated cost, closing balance | 54,276 | 54,276 | - | - |
| Depreciation opening balance | -12,664 | -1,809 | - | - |
| Depreciation for the year | -10,855 | -10,855 | - | - |
| Accumulated depreciation, closing balance | -23,519 | -12,664 | - | - |
| **Carrying amount** | **30,757** | **41,612** | **-** | **-** |

## Note 7

| Machinery and other technical equipment | Group | | Parent company | |
|---|---|---|---|---|
| | 2021-12-31 | 2020-12-31 | 2021-12-31 | 2020-12-31 |
| Cost opening balance | 3,136 | 999 | - | - |
| Purchase | 1,285 | 2,137 | - | - |
| Accumulated cost, closing balance | 4,421 | 3,136 | - | - |
| Depreciation opening balance | -674 | -55 | - | - |
| Depreciation for the year | -1,308 | -619 | - | - |
| Accumulated depreciation, closing balance | -1,982 | -674 | - | - |
| Translation difference | -86 | -131 | - | - |
| **Carrying amount** | **2,353** | **2,331** | **-** | **-** |

## Note 8

| Equipment, tools, fixtures and fittings | Group | | Parent company | |
|---|---|---|---|---|
| | 2021-12-31 | 2020-12-31 | 2021-12-31 | 2020-12-31 |
| Cost opening balance | 3,253 | 110 | - | - |
| Purchase | 421 | 3,143 | - | - |
| Accumulated cost, closing balance | 3,674 | 3,253 | - | - |
| Depreciation opening balance | -434 | -7 | - | - |
| Depreciation for the year | -1,356 | -427 | | |
| Accumulated depreciation, closing balance | -1,790 | -434 | - | - |
| Translation difference | 64 | 17 | - | - |
| **Carrying amount** | **1,948** | **2,836** | **-** | **-** |

## Note 9

| Specification of participation in group companies<br>Parent company | | 2021 | | 2020 | |
|---|---|---|---|---|---|
| **Company name**<br>**Reg. No.** | **Registered office** | **Number/ Voting %** | **Carrying amount** | **Number/ Voting %** | **Carrying amount** |
| Qlife Aps<br>CVR number 39982277 | Denmark | 85,921/100 | 68,024 | 85,921/100 | 68,024 |
| **Information about equity and profit/loss** | | **Equity** | **Profit/loss** | **Equity** | **Profit/loss** |
| Qlife Aps | | 54,273 | -30,446 | 42,882 | -8,369 |
| **Information about aquisition value Qlife Aps** | | | | | |
| Cost opening balance | | 108,500 | | 68,024 | |
| Shareholders contribution | | 41,259 | | 40,476 | |
| Accumulated cost, closing balance | | 149,759 | | 108,500 | |
| Accumulated depreciation, opening balance | | -40,476 | | - | |
| Deperciation of investment in subsidiary | | -41,259 | | -40,476 | |
| Accumulated depreciation, closing balance | | -81,735 | | -40,476 | |
| **Carrying amount** | | **68,024** | | **68,024** | |

## Note 10

| Receivables from group companies | Group | | Parent company | |
|---|---|---|---|---|
| | 2021-12-31 | 2020-12-31 | 2021-12-31 | 2020-12-31 |
| Cost opening balance | - | - | 5,168 | 3,572 |
| Additional | - | - | 57,477 | 42,072 |
| Convert receivables to shareholders' contribution | - | - | -41,259 | -40,476 |
| **Carrying amount** | **-** | **-** | **21,386** | **5,168** |

## Note 11

| Prepaid expenses and accrued income | Group | | Parent company | |
|---|---|---|---|---|
| | 2021-12-31 | 2020-12-31 | 2021-12-31 | 2020-12-31 |
| Software | 1,416 | - | - | - |
| Manufacturing expenses | 1,242 | - | - | |
| Deposit rental expenses | 3,755 | 1,174 | - | - |
| Other prepaid expenses | 797 | 674 | 8 | 8 |
| | **7,210** | **1,848** | **8** | **8** |

## Note 12

| Information about share capital | No shares | Quota value |
|---|---|---|
| Number/value beginning of the year | 11,174,438 | 0.08 |
| Share issue | 4,310,489 | 0.08 |
| **Number/value end of the year** | **15,484,927** | **0.08** |

## Note 13

| Long-term liabilities | Group | | Parent company | |
|---|---|---|---|---|
| | 2021-12-31 | 2020-12-31 | 2021-12-31 | 2020-12-31 |
| Other long-term liabilities | 2,763 | 3,348 | - | - |
| Amortisation within 1 year | - | - | - | - |
| Amortisation within 2 to 5 year | 2,763 | 3,348 | - | - |
| Amortisation after 5 year | - | - | - | - |
| | | | | |
| Total amortisation within 1 year | - | - | - | - |
| Total amortisation within 2 to 5 year | 2,763 | 3,348 | - | - |
| Total amortisation after 5 year | - | - | - | - |

## Not 14

| Accrued expenses and deferred income | Group | | Parent company | |
|---|---|---|---|---|
| | 2021-12-31 | 2020-12-31 | 2021-12-31 | 2020-12-31 |
| Salary related expenses | 2 846 | 2 627 | - | 256 |
| Other accrued expenses | 639 | 536 | 391 | 361 |
| Prepaid income project support | 11 951 | - | - | - |
| | **15 436** | **3 163** | **391** | **617** |

## Note 15

| Pledged assets | Group | | Parent company | |
|---|---|---|---|---|
| | 2021-12-31 | 2020-12-31 | 2021-12-31 | 2020-12-31 |
| Floating charge | 4,126 | 4,048 | 0 | 0 |

## Note 16

| Definition key ratios |
|---|

Equity ratio:

Adjusted equity in relation to balance sheet total, %

Helsingborg den 6 April 2022

Mette Gross
Chairman

John Andersson Moll

Ulrik Harrysson

Mette-Marie Harild

Mikael Persson

Thomas Warthoe
CEO

Our auditor's report was submitted on 6 April 2022

Olof Andersson
Chartered Accountant

Jörgen Lövgren
Chartered Accountant

# AUDITOR'S REPORT

To the general meeting of the shareholders of Qlife Holding AB

Corporate identity number 559224-8040

## Report on the annual accounts and consolidated accounts

### Opinions

We have audited the annual accounts and consolidated accounts of Qlife Holding AB for the year 2021. The annual accounts and consolidated accounts of the company are included on pages 30-47 in this document.

In our opinion, the annual accounts and consolidated accounts have been prepared in accordance with the Annual Accounts Act and present fairly, in all material respects, the financial position of parent company and the group as of 31 December 2021 and their financial performance and cash flow for the year then ended in accordance with the Annual Accounts Act. The statutory administration report is consistent with the other parts of the annual accounts and consolidated accounts.

We therefore recommend that the general meeting of shareholders adopts the income statement and balance sheet for the parent company and the group.

### Basis for Opinions

We conducted our audit in accordance with International Standards on Auditing (ISA) and generally accepted auditing standards in Sweden. Our responsibilities under those standards are further described in the "Auditor's Responsibilities" section. We are independent of the parent company and the group in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled our ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinions.

### Other Information than the annual accounts and consolidated accounts

The Board of Directors and the Managing Director are responsible for the other information. The other information comprises pages 1-29 and 50-52 (but does not include the annual accounts, consolidated accounts and our auditors' report thereon.)

Our opinion on the annual accounts and consolidated accounts does not cover this other information and we do not express any form of assurance conclusion regarding this other information.

In connection with our audit of the annual accounts and consolidated accounts, our responsibility is to read the information identified above and consider whether the information is materially inconsistent with the annual accounts and consolidated accounts. In this procedure we also take into account our knowledge otherwise obtained in the audit and assess whether the information otherwise appears to be materially misstated.

If we, based on the work performed concerning this information, conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

### Responsibilities of the Board of Directors and the Managing Director

The Board of Directors and the Managing Director are responsible for the preparation of the annual accounts and consolidated accounts and that they give a fair presentation in accordance with the Annual Accounts Act. The board of Directors and the Managing Director are also responsible for such internal control as they determine is necessary to enable the preparation of annual accounts and consolidated accounts that are free from material misstatement, whether due to fraud or error.

In preparing the annual accounts and consolidated accounts, the Board of Directors and the Managing Director are responsible for the assessment of the company's and the group's ability to continue as a going concern. They disclose, as applicable, matters related to going concern and using the going concern basis of accounting. The going concern basis of accounting is however not applied if the Board of Directors and the Managing Director intends to liquidate the company, to cease operations, or has no realistic alternative but to do so.

### Auditor's responsibility

Our objectives are to obtain reasonable assurance about whether the annual accounts and consolidated accounts as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinions. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and generally accepted auditing standards in Sweden will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual accounts and consolidated accounts.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the annual accounts and consolidated accounts, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinions. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of the company's internal control relevant to our audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors and the Managing Director.
- Conclude on the appropriateness of the Board of Directors' and the Managing Director's use of the going concern basis of accounting in preparing the annual accounts and consolidated accounts. We also draw a conclusion, based on the audit evidence obtained, as to whether any material uncertainty exists related to events or conditions that may cast significant doubt on the company's and the group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the annual accounts and consolidated accounts or, if such disclosures are inadequate, to modify our opinion about the annual accounts and consolidated accounts.

Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause a company and a group to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the annual accounts and consolidated accounts, including the disclosures, and whether the annual accounts and consolidated accounts represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient and appropriate audit evidence regarding the financial information of the entities or business activities within the group to express an opinion on the consolidated accounts. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our opinions.

We must inform the Board of Directors of, among other matters, the planned scope and timing of the audit. We must also inform of significant audit findings during our audit, including any significant deficiencies in internal control that we identified.

# Report on other legal and regulatory requirements

## Opinions

In addition to our audit of the annual accounts and consolidated accounts, we have also audited the administration of the Board of Directors and the Managing Director of Qlife Holding AB for the year 2021 and the proposed appropriations of the company's profit or loss.

We recommend to the general meeting of shareholders that the profit be appropriated in accordance with the proposal in the statutory administration report and that the members of the Board of Directors and the Managing Director be discharged from liability for the financial year.

## Basis for Opinions

We conducted the audit in accordance with generally accepted auditing standards in Sweden. Our responsibilities under those standards are further described in the "Auditor's Responsibilities" section. We are independent of the parent company and the group in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled our ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinions.

## Responsibilities of the Board of Directors and the Managing Director

The Board of Directors is responsible for the proposal for appropriations of the company's profit or loss. At the proposal of a dividend, this includes an assessment of whether the dividend is justifiable considering the requirements which the company's and the group's type of operations, size and risks place on the size of the parent company's and the group's equity, consolidation requirements, liquidity and position in general.

The Board of Directors is responsible for the company's organization and the administration of the company's affairs. This includes among other things continuous assessment of the company's and the group's financial situation and ensuring that the company's organization is designed so that the accounting, management of assets and the company's financial affairs otherwise are controlled in a reassuring manner. The Managing Director shall manage the ongoing administration according to the Board of Directors' guidelines and instructions and among other matters take measures that are necessary to fulfill the company's accounting in accordance with law and handle the management of assets in a reassuring manner.

## Auditor's responsibility

Our objective concerning the audit of the administration, and thereby our opinion about discharge from liability, is to obtain audit evidence to assess with a reasonable degree of assurance whether any member of the Board of Directors or the Managing Director in any material respect:

- has undertaken any action or been guilty of any omission which can give rise to liability to the company, or
- in any other way has acted in contravention of the Companies Act, the Annual Accounts Act or the Articles of Association.

Our objective concerning the audit of the proposed appropriations of the company's profit or loss, and thereby our opinion about this, is to assess with reasonable degree of assurance whether the proposal is in accordance with the Companies Act.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with generally accepted auditing standards in Sweden will always detect actions or omissions that can give rise to liability to the company, or that the proposed appropriations of the company's profit or loss are not in accordance with the Companies Act.

As part of an audit in accordance with generally accepted auditing standards in Sweden, we exercise professional judgment and maintain professional scepticism throughout the audit. The examination of the administration and the proposed appropriations of the company's profit or loss is based primarily on the audit of the accounts. Additional audit procedures performed are based on our professional judgment with starting point in risk and materiality. This means that we focus the examination on such actions, areas and relationships that are material for the operations and where deviations and violations would have particular importance for the company's situation. We examine and test decisions undertaken, support for decisions, actions taken and other circumstances that are relevant to our opinion concerning discharge from liability. As a basis for our opinion on the Board of Directors' proposed appropriations of the company's profit or loss we examined whether the proposal is in accordance with the Companies Act.

Malmö 6 April 2022

| | |
|---|---|
| Olof Andersson | Jörgen Lövgren |
| Authorized Public Accountant | Authorized Public Accountant |

# BOARD

The Board of Directors in Qlife Holding consists of John Moll, Ulrik Harrysson, Thomas Warthoe, Mette-Marie Harild, Mette Gross (Chair) and Mikael Persson.

The Board covers extensive experience from the med-tech and diagnostics industry, within supply chain, sales, business development, finance and management.

*Front:* Mette-Marie Harild, Mette Gross, Mikael Persson. *Back:* John Moll, Ulrik Harrysson, Thomas Warthoe.

John Moll *is an entrepreneur and experienced business angel with a focus on life science. John has founded and sold two companies and is a board member of three biotech companies in Sweden and Denmark.*

Ulrik Harrysson *is CEO of SyntheticMR and has through his career gained international experience from management roles in global companies such as Hermes Medical Solution, HemoCue, Danaher and Pfizer.*

Thomas Warthoe *is CEO of Qlife and one of the original founders of Qlife and holds 9.7% ownership of the company. Thomas has considerable experience in the diagnostics industry and has developed three biotech companies earlier in his career.*

Mette-Marie Harild *is a board professional and has sustained experience of leading international organisations within the pharma/ medical industry, most recently from Medtronic as Regional Vice President ABGI & Nordic.*

Mette Gross *(Chair) has extensive experience from small and large companies as CFO and has in recent years been involved in developing and listing three medical-technology companies. Mette is a board member in three other medical-technology companies in Sweden and Denmark.*

Mikael Persson *is EVP Supply Chain & Product development at Arjo and has broad global experience in the med-tech industry in senior positions in Supply Chain and Product Development from Alfa Laval, Cardo Flow Solutions, Flûgger A/S, and Getinge.*

# MANAGEMENT

The Management team in Qlife consist of Thomas Warthoe (CEO), Peter Warthoe (CSO), Jakob Broberg Lind (Sales), Maiken Worsøe Rosenstierne (R&D), Kristina Christensen (QA/RA), John Søndergård (Operations) and Kasper Boel Rousøe (CFO).

The experienced team holds solid academic education and many years of experience in their respective fields.

Thomas Warthoe
*CEO, CO-Founder*

Peter Warthoe
*CSO, CO-Founder*

Jakob Broberg Lind
*Sales*

Maiken Worsøe Rosenstierne
*R&D*

Kristina Christensen
*QA/RA*

John Søndergård
*Operations*

Kasper Boel Rousøe
*CFO*

**Peter Warthoe** *is an entrepreneur who has co-founded companies in life science, diagnostics, and technology. Peter is a prominent scientist and has been quoted in a variety of scientific writings and has been mentioned more than a thousand times for his discovery of a gene-profiling technique. Peter has made more than ten patent applications.*

**Jakob Broberg Lind** *is a Senior Healthcare Executive with many years' experience with business development and strategic sales within medical devices. He brings a solid record of results and success from leading companies such as Boston Scientific and Medtronic.*

**Maiken Worsøe Rosenstierne** *is a Virologist and Biochemist with an MSc and PhD Career: Postdoc at University of Copenhagen and at Roskilde University. Maiken was previously a Senior Scientist at Statens Serum Institut and is a respected scientist and a solid leader of multiple R&D projects and our large R&D department.*

**Kristina Christensen** *has extensive experience in IVD and Medical Devices within the areas of Quality Assurance, Design Control, Risk Management, Product Development of reagents and instruments and clinical evaluations.*

**John Søndergård** *is a Senior Executive from the med-tech and pharma industry with more than 30 years of international management and leadership experience within Manufacturing and R&D.*

**Kasper Boel Rousøe** *joined Qlife on 1 March, 2022, bringing more than 20 years of experience from leading roles in the financial area. Kasper holds an MSc in Economics from Copenhagen University and an EMBA from Lausanne in Switzerland.*

Qlife

qlifeholding.com